H-IVIG Treatment for Severe H1N1 2009

• Mortality [ Time Frame: From date of randomization until the date of death from any cause during hospitalization, assessed up to 6 months ] [ Designated as safety issue: No ]
  

• Adverse events [ Time Frame: From date of randomization until the date of first documented adverse events due to treatment, assessed up to 1 week ] [ Designated as safety issue: Yes ]
  To assess the safety of H-IVIG and IVIG treatment
  
  
• ICU length of stay [ Time Frame: Participants will be followed for the duration of ICU stay, an expected average of 4 weeks ] [ Designated as safety issue: No ]
  
• Hospital length of stay [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 12 weeks ] [ Designated as safety issue: No ]
  
• Nasopharyngeal viral load [ Time Frame: One day before randomization and up to 5 days after treatment ] [ Designated as safety issue: No ]
  To assess the change in nasopharyngeal viral load one day before randomization and 5 days after treatment
  
  
• Cytokine/ chemokine [ Time Frame: One day before randomization and up to 5 days after treatment ] [ Designated as safety issue: No ]
  To assess the change in cytokine/ chemokine response one day before randomization and 5 days after treatment
  
  

Since the emergence of the novel swine origin influenza A virus (H1N1 2009) in Mexico in March 2009, the virus has led to a pandemic in over 170 countries, resulting in over 180 thousands microbiologically confirmed cases and over 18000 mortality. This strain represents a quadruple re-assortment of two swine strains, one human strain, and one avian strain of influenza. Although the H1N1 2009 is causing a mild disease and has a relatively low mortality rate currently in Hong Kong, severe cases have been reported.

Patients infected with severe H1N1 2009 have overwhelmed the intensive care services in these countries and the mortality has rose up to 6% in Argentina and Brazil, and 0.4% in Australia. This is very much higher than the 0.06% mortality rate of the seasonal flu. Furthermore, there were reports of H1N1 2009 oseltamivir resistance and zanamivir is difficult to be delivered to the consolidated lungs in the severe cases when such drug is most needed. In Hong Kong, vaccination for the H1N1 2009 was prioritised to the older people aged 65 or above with chronic illness, younger people with chronic illness and health care workers. The healthy adults aged 18 to 65, who are most at risk of developing severe H1N1 2009 was not covered by the vaccination program. Experience from 1918 H1N1 pandemic and single case report on the treatment for severe H5N1 infection (Zhou et al. 2007) showed that hyperimmune convalescent plasma is useful (Luke et al. 2006). Mice experiments also showed that antibody therapy is highly effective in the case of H5N1 infection (Heltzer ML et al. 2009, Writing Committee of the Second World Heath Organization, 2008). Therefore, convalescent plasma from patients recovered from H1N1 2009 infection can be harvested to prepare for hyperimmune intravenous immunoglobulin (H-IVIG) and the prepared H-IVIG can be assessed in a randomised controlled trial for treatment of patients with severe H1N1 2009 infection.